10.27.25 -- CDMO Opportunities And Threats Report

To prevent path-to-market setbacks, it is critical to develop a Chemistry, Manufacturing, and Controls (CMC) strategy that proactively identifies scientific and compliance gaps, as well as mitigates risk.

Review an innovative method for fast-tracking AAVs through a flexible platform approach that easily scales as the project advances from early development to late-stage GMP production and to market.

Learn about the development of a serum-free suspension MDCK cell line that serves as an optimal platform for isolating human influenza viruses from clinical samples and producing vaccines at scale.

Lentiviral vector manufacturing is complex and highly regulated, which is why a specialized CDMO is required to ensure safe, scalable, and compliant production from early development to commercialization.

Boost rAAV yields and quality while significantly reducing production costs with our proprietary HEK293 cell line and scalable, optimized manufacturing platform tailored for gene therapy applications.

Discover insights tailored specifically for drug product researchers and manufacturers, offering key knowledge on extractables, leachables, and effective implementation strategies to ensure product safety and compliance.

Observe how to transform biopharma learning with a human-centered, AI-enhanced ecosystem that intelligently personalizes development, fosters deeper engagement, and aligns training with real-world impact.

As advanced therapies grow more complex, CDMOs must move beyond fragmented logistics and embrace integrated supply chain partnerships to ensure scalability, compliance, and long-term success.

Review the results obtained for our proprietary HEK293T 2G7 suspension cell line for LVV production by transient transfection in serum-free, chemically-defined and animal component-free media.